Mark Bogart Joins B-Secur as Senior Vice President of U.S. Healthcare

Ex-AliveCor executive’s new role will focus on furthering the medical strategy of the heart health technology company

Mark Bogart is the new Senior Vice President (SVP) of B-Secur’s U.S. Healthcare and will help to expand the company’s footprint in the U.S. market.

Mark Bogart will identify, develop, and build long-term agreements with medical device and digital health companies as well as cultivate and manage customer relationships with existing partners. He will also focus on delivering the company’s medical strategy for its newly launched HeartKey® 2.0 technology.

Launched in April at Heart Rhythm 2022, HeartKey® 2.0 significantly reduces EKG signal noise, elevating EKG interpretation to new heights of efficiency and accuracy for clinicians and facilitating the trend towards greater remote cardiac monitoring. It also offers a range of FDA-cleared health algorithms and actionable wellness insights.

Mark Bogart said:

“Supported by a best-in-class engineering and product development team, B-Secur is at the forefront of signal conditioning and EKG rhythm analysis.”

“The opportunity to engage and bring forward HeartKey® 2.0 creates tremendous opportunities across the U.S. Medtech space and ultimately improves workflow, patient care and clinical outcomes. It’s a game changer for the industry and our physician providers.”

Mark Bogart joins B-Secur from AliveCor where he served as a SVP of the U.S. Healthcare Division. In his previous role, he helped establish KardiaMobile® 6L in the B2B markets, validated a direct reimbursement model, and developed new sales and strategic opportunities with KOL’s, leading healthcare systems, and progressive companies in digital health. He joins B-Secur with an impressive track record of working with corporate, small, and scale-up businesses and believes the company’s new technology has the power to evolve the cardiovascular space.

B-Secur’s Chief Commercial Officer, Ben Carter said he is delighted Mark Bogart has joined the company to help grow the business in the U.S.

He said: “Since the launch of HeartKey® 2.0 we have seen a strong growing demand across our key consumer and medical customers.

“Mark brings a wealth of leadership and business experience from across the medical industry. He has worked with some of the biggest medical device and platform companies in the world and has deep medical industry knowledge. I’m excited that Mark has agreed to join B-Secur and I look forward to working with him as we continue to grow our business, especially in the U.S.”

Founded in Belfast, Northern Ireland, B-Secur employs almost 100 people across offices in the U.S., the UK and Ireland. The innovative biosensing algorithm company licences its technology to a number of medical and consumer technology customers.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.